Trump Just Opened Up A $400 BILLION Market (Get In Now) | Stanley Druckenmiller

Añadido: 2026-05-23

[00:00:00]Trump signed an executive order in April of last year and 99% of industries completely ignored it.

[00:00:06]They were busy watching the headlines, debating tariffs, arguing about interest rates, doing exactly what broke people do, reacting to noise instead of following where the actual money is flowing.

[00:00:17]That order cracked open a $400 billion market that has been locked shut for 40 years. 40 years.

[00:00:24]And right now in in 2026, you are sitting at the beginning of what could be one of the most significant wealth creation windows of this entire decade.

[00:00:34]I have watched markets for over 40 years. I have seen what happens when a regulatory door opens on a category that has suppressed demand, proven clinical outcomes, and institutional money waiting on the sidelines. What happens is simple.

[00:00:51]Early investors get very, very rich, and everyone who waited for the mainstream media to tell them about it buys at the top and complains about it for the rest of their lives. That is the pattern.

[00:01:02]That has always been the pattern.

[00:01:05]The question today is which side of that pattern are you going to be on? If you're not subscribed to this channel, you are making a financial mistake right now.

[00:01:15]The kind of intelligence I'm breaking down in this video, the frameworks, the specific tickers, the exact math, financial advisors charge thousands of dollars to give you a watered-down version of this.

[00:01:27]You can have all of it, every single video, completely free just by hitting the subscribe button. That is the most asymmetric trade available to you today.

[00:01:36]Do it now, then come back, and we will continue. Let me tell you exactly what happened on April 18th, 2025, because the details of that executive order matter enormously, and almost nobody has actually read them or understood their financial implications. Donald Trump signed an order that did three specific things.

[00:01:57]First, it fast-tracked a brand new category of mental health treatment called psychedelic-assisted therapy for federal regulatory review. Second, it allocated $50 in direct research funding to this category.

[00:02:11]Third, and this is the one that the financial press almost entirely missed, certain drugs within this category were designated as national priority treatments and handed priority review voucher status by the FDA. Now, if you do not know what a priority review voucher is, let me educate you because this is where the money lives. A priority review voucher essentially cuts the FDA approval timeline significantly.

[00:02:37]It is the regulatory equivalent of cutting to the front of a line that normally takes years, and in the pharmaceutical business, time is money in the most literal sense imaginable.

[00:02:48]Every month a drug sits waiting for approval is a month of revenue that does not exist. When you hand a company a priority review voucher, you are handing them time, and time in this industry translates directly into billions of dollars of earlier revenue. The market understood this immediately.

[00:03:06]Three small biotech stocks tied directly to this order jumped between 20 and 50% the single day after that order was signed.

[00:03:14]Compass Pathways, ticker CMPS, ATAI Life Sciences, ticker ATAI, GH Research, ticker GHRS.

[00:03:23]They spiked, the news cycle moved on within 72 hours.

[00:03:28]The attention-deficit financial media found something else to be outraged about, and those stocks quietly pulled back, and that pullback, that moment of public forgetting, is exactly where opportunity lives for people who actually know what they are looking at.

[00:03:45]The question is not whether Trump caused this.

[00:03:48]He did not cause this. The FDA has been approving more new mental health treatments in the last 5 years than it did in the prior 40 years combined.

[00:03:57]Lawmakers from both parties, which in 2026 is a genuinely rare thing, have been introducing bipartisan legislation on mental health and veteran care. RFK Jr., who runs the Department of Health and Human Services, has been an open and aggressive public advocate for alternative treatment modalities.

[00:04:18]Trump's order was not the spark.

[00:04:20]It was the signal that the institutional and political infrastructure now fully supports what science has already been building toward for years. When you have the science, the clinical data, the political will, and the regulatory momentum all pointing in the same direction at the same time, that is not speculation.

[00:04:42]That is a convergence.

[00:04:44]And convergences produce the biggest returns in financial markets. Before I give you the three stocks, I need to give you the proof that this entire category works at commercial scale.

[00:04:54]Because without this proof, you are just gambling on hope, and I do not gamble on hope. I gamble on evidence.

[00:05:02]The evidence here is a company called Johnson & Johnson.

[00:05:06]You know them. Baby powder, Band-Aid, the most boring blue chip stock in America. But inside that boring company is a data point that changes everything about how you should think about psychedelic assisted therapy as an investable market.

[00:05:20]In 2019, Johnson & Johnson received FDA approval for a drug called Spravato.

[00:05:27]It is a nasal spray derived from ketamine, which is a dissociative anesthetic with psychedelic properties.

[00:05:35]It was designed specifically for treatment-resistant depression patients who have tried multiple standard antidepressants and gotten no meaningful benefit.

[00:05:46]When this drug launched, the consensus opinion from every analyst and every industry commentator was that it would fail commercially.

[00:05:55]The price point was $590 per dose.

[00:05:58]Patients needed it twice a week for the first month. The UK's regulatory watchdog refused to recommend it, calling it too expensive.

[00:06:07]The headlines were brutal.

[00:06:09]The narrative was unanimous. Insurance companies will never pay for this.

[00:06:13]The price is indefensible.

[00:06:15]This product is dead on arrival.

[00:06:18]I want you to remember that narrative because in the first quarter of 2026, that dead on arrival drug generated nearly $500 million in a single quarter.

[00:06:28]That is almost $2 billion in annualized revenue, growing at nearly 50% year-over-year.

[00:06:36]Bloomberg recently called it Johnson & Johnson's blockbuster psychedelic drug.

[00:06:42]I bought Johnson & Johnson late last year specifically because of this drug.

[00:06:46]I sold it after locking in approximately 40% gains. And before you ask why I sold a stock that is generating $2 billion a year in revenue, the answer is mathematics. Johnson & Johnson is worth hundreds of billions of dollars. Adding $2 billion in drug revenue to a company that size barely registers in the stock price. You get a decent return. You take it and you deploy it somewhere where the same revenue would be transformative instead of incremental.

[00:07:15]But what Johnson & Johnson proved is not just that one drug can make money. It proved that the three things everyone said would stop this category are simply not true.

[00:07:26]Insurance companies do pay for these treatments. Patients do seek them out aggressively. And you absolutely can charge premium prices for drugs that work on treatment-resistant conditions where nothing else has worked. That is the proof of concept. That is the established precedent. And now the regulatory door is open for smaller companies to follow the exact same path.

[00:07:48]Now, I'm going to give you the mathematics because the math is where this story goes from interesting to genuinely extraordinary.

[00:07:56]There are approximately 280 million people globally living with serious depression. Of those 280 million, roughly 30% minus That is about 85 million people do not respond adequately to standard antidepressant treatment. Let me give you a number you can wrap your head around. 85 million people is the entire population of Germany, an entire country's worth of human beings who have been prescribed medication after medication, experience side effects, gain no meaningful therapeutic benefit, and are still suffering.

[00:08:32]The system has no answer for them, and that is before you factor in PTSD, severe anxiety disorders, and addiction, which are all conditions being targeted by this same category of psychedelic-derived treatments, and which add tens of millions more patients to the addressable base.

[00:08:50]Wall Street's estimate of the total addressable market for psychedelic-assisted mental health therapy is $400 Now, here is where I need you to focus because this is the mathematical argument for why the small companies matter infinitely more than Johnson & Johnson in terms of your potential return.

[00:09:11]COMPASS Pathways, which I will cover in detail in a moment, is currently trading at a market capitalization of approximately $1 billion.

[00:09:20]Johnson & Johnson is guiding toward $5 billion in annual Spravato revenue within their forecast horizon. Let us be conservative.

[00:09:28]Let us say COMPASS captures only 20% of what Johnson & Johnson is projecting.

[00:09:35]That is $1 billion in annual revenue for company currently worth $1 billion.

[00:09:42]Pharmaceutical companies with patent protected drugs and no generic competition typically trade at five to 10 times their annual revenue. So at $1 billion in revenue and a five times multiple, you are looking at a $5 billion company from where it sits today at $1 billion.

[00:09:59]That is a five times return on a conservative scenario at a 10 times revenue multiple, which is entirely normal for high-growth biotech. You're looking at a $10 billion company. That is a 10 times return.

[00:10:13]And if Compass approaches Johnson & Johnson's actual numbers rather than 20% of them, the mathematics becomes numbers that I will not put in this video because I do not want to be accused of reckless promotion. What I will tell you is that the math works.

[00:10:30]The math works on conservative assumptions, and the math works because Johnson & Johnson already proved that the revenue is real, the insurance coverage is real, and the pricing power is real.

[00:10:42]You are not speculating about whether a market exists. You are positioning ahead of smaller companies entering a market whose existence has already been validated by one of the largest pharmaceutical companies on Earth. Now, let us go through the three stocks with precision because understanding what each one is and what each one is not is the difference between making an intelligent, calculated speculation and buying lottery tickets. I run every company through three filters before I consider touching it.

[00:11:14]Filter one, profit per sale, which is gross margin. How much of every revenue dollar the company actually keeps after the cost of making the product. For a real pharmaceutical company with a patent protected drug, you are looking for 70% or better.

[00:11:31]Filter two, patent durability. How many years of legal protection does the drug have before a competitor can legally copy it and destroy the pricing power?

[00:11:41]Anything under 10 years is borderline.

[00:11:44]15 years or more is what you want.

[00:11:47]Filter three, is the drug currently selling?

[00:11:50]I have a strong preference for companies generating real revenue over companies still in trials because trials are binary events dependent on FDA judgment calls and binary events can go to zero.

[00:12:02]Let me run all three stocks through these filters honestly, including where they fail because if I only tell you the good news, I am not giving you intelligence, I am giving you a sales pitch. Compass Pathways, ticker CMPSS.

[00:12:15]This is the furthest along of the three and therefore the one with the clearest near-term catalyst. Their drug is called COMP360, which is a synthetic pharmaceutical grade version of psilocybin, the active compound in magic mushrooms, specifically engineered for treatment-resistant depression. The same patient population that Johnson & Johnson's Spravato targets. The drug is administered as a single dose in a clinical setting and the therapeutic effects have been studied out to 26 weeks, which is a longer durability window than any prior psychedelic clinical study has examined. They have completed phase three trials and the data falls within the range the FDA has historically accepted for drugs in their this category. The expectation in 2026 is FDA approval, either late this year or early 2027.

[00:13:07]If that approval lands, Compass becomes the first company in history to have a classic psychedelic, a genuine psilocybin-derived compound approved by the FDA. That is not a minor milestone.

[00:13:20]That is a category-defining event.

[00:13:24]Now, through my filters, gross margin, we do not have data because they are pre-revenue, patent protection. They hold multiple patents covering the formulation, the dosing protocol, and the manufacturing process, which is a more defensible position than a single compound patent. But, the real test only comes when a competitor challenges it in court currently selling now. So, Compass fails two of my three filters. That is important to acknowledge. But, the reason Compass sits at the top of this list is that the catalyst calendar is the clearest FDA approval, commercial launch, insurance reimbursement decisions. Those are the specific events that will move this stock violently in one direction or the other. Look at the chart. This stock was trading at $60 in 2021. It crashed 83% to below $4. It is currently trading around $10.

[00:14:22]I want you to understand something about that chart pattern, because most investors look at it and see a broken company.

[00:14:30]I look at it and see a classic innovation stock that got priced at peak euphoria, crashed when timelines extended, bottomed out in the zone of maximum investor boredom, and is now beginning the recovery phase that precedes the real move.

[00:14:47]This is the exact same structure I saw in quantum computing stocks before they made their enormous runs.

[00:14:53]Recency is not an advantage here. The fact that this stock has done nothing for years is exactly what makes the setup cleaner, not worse. Atai Life Sciences, ticker ATI, is what I would call the platform bet or the diversified bet within this category. Where Compass is a single drug, single indication company, Atai has constructed what is essentially a venture portfolio of five separate drug programs in clinical development across multiple conditions.

[00:15:23]This is important for a specific reason.

[00:15:25]If you are worried about the binary risk of one FDA approval process, Atai gives you five separate shots at the target.

[00:15:33]One compound can fail and you still have four remaining.

[00:15:37]They also merged with Beckley Neuroscience in late 2024, which broadened the pipeline further and added scientific credibility to the platform.

[00:15:46]The company is backed by Peter Thiel, which matters because Peter Thiel does not write checks into things. He has not researched with ruthless thoroughness and because his backing signals access to capital and political connections that smaller biotechs frequently lack.

[00:16:02]Critically, Atai holds a stake in Compass and licenses Compass's drug for certain geographic territories, which means if you buy Atai, you are getting partial exposure to Compass's pipeline, whether you intend to or not. This is the diversified version of the same bet.

[00:16:20]Through my filters, no meaningful revenue yet. So, gross margin data does not exist.

[00:16:26]Patent protection is spread across five separate compound portfolios, which is actually a structural advantage over a single patent company.

[00:16:34]But each individual compound still needs to survive its own legal challenges.

[00:16:40]Currently selling, no.

[00:16:42]Atai fails the same two filters Compass fails. The chart tells a similar story.

[00:16:47]It ran up to around $23, gave back essentially everything, currently trading near its listing price. Atai is the lower concentration, broader exposure way to participate in this category if the binary risk of a single FDA decision is more than you're comfortable with. GH Research, ticker GHRS, is the technology bet. Their entire platform is built around a single compound called 5-MeO-DMT, which is a psychedelic that acts through a fundamentally different mechanism than psilocybin and produces effects over a dramatically shorter period of time.

[00:17:24]The treatment session for a Compass drug takes 6 to 8 hours in a clinical setting.

[00:17:29]The treatment session for a GH research drug, if the clinical data holds up, takes approximately 30 minutes. I need you to understand the commercial significance of that difference because it is not just a patient convenience issue, it is a unit economics revolution for every clinic that wants to offer these treatments. A clinic running 6 to 8 hour sessions can see a limited number of patients per day per treatment room.

[00:17:57]A clinic running 30 minute sessions can see dramatically more patients in the same physical space with the same staff.

[00:18:05]Faster sessions mean more patients per clinic, which means faster commercial adoption, which means faster revenue ramp, which means faster path to the valuation inflection point. Through my filters, no revenue, one compound with one mechanism, which is a higher concentration patent risk than a ties five program structure, and not currently selling.

[00:18:25]GH research carries the highest technical risk of the three because it is the most concentrated bet on a single novel compound. But if that compound performs in commercial deployment the way the early data suggests it might, the commercial adoption curve could be steeper than either of the other two names. Now I need to give you the part that most financial content creators skip because it makes the story less exciting. And I am going to give it to you because I am not here to excite you.

[00:18:51]I am here to make you money, and making money requires understanding risk with the same clarity you apply to opportunity.

[00:18:59]There are five specific risks in this category, and you need to hold all five in your head simultaneously.

[00:19:05]First, FDA approval is not guaranteed.

[00:19:10]I believe approval is probable for Compass based on the phase three data and the current regulatory environment.

[00:19:17]Probability is not certain.

[00:19:19]Drugs fail at the final approval stage for reasons that are sometimes scientific and sometimes political and sometimes completely arbitrary.

[00:19:28]If Compass does not get FDA approval, the stock goes back toward $4 or lower and you lose the majority of whatever you invested.

[00:19:38]That outcome is possible and you need to be financially and psychologically prepared for it before you invest a single dollar.

[00:19:45]Second, dilution risk.

[00:19:48]Every pre-revenue biotech company needs to raise capital to fund its operations between now and the point where drug sales generate enough cash flow to sustain the business.

[00:19:58]When they raise that capital, they issue new shares and every new share issued reduces the percentage of the company that your existing shares represent.

[00:20:07]This is the pharmaceutical equivalent of inflation.

[00:20:11]It is legal, it is normal, and it will happen.

[00:20:15]The question is whether the dilution is manageable or catastrophic and that depends on how well capitalized these companies are right now and how efficiently they burn through cash.

[00:20:24]Third, commercial adoption risk. Getting FDA approval does not automatically mean the drug sells. Physicians need to be educated on the treatment protocol.

[00:20:33]Clinics need to be equipped and trained to administer it. Insurance companies need to formally add it to their reimbursement schedules and patients need to both know it exists and be willing to pursue a psychedelic assisted treatment pathway.

[00:20:47]Johnson & Johnson Spravato took years to ramp from approval to meaningful revenue. These companies will face the same ramp period and investors who expect immediate revenue post approval will be disappointed.

[00:21:01]Fourth, political risk.

[00:21:04]The current regulatory and political environment is the most favorable this category has ever seen.

[00:21:10]That can change. A different administration, a different HHS secretary, a high-profile adverse event in a clinical setting that generates negative media coverage. Any of these things can shift the political climate and slow the regulatory momentum that is currently working in this category's favor.

[00:21:31]Fifth, competitive risk.

[00:21:34]Johnson & Johnson is not a passive observer. They have a commercially successful drug, massive distribution infrastructure, and the financial resources to lobby, litigate, and outspend every small biotech in this category simultaneously.

[00:21:51]Underestimating the competitive pressure would be naive. Given all of this, here is the only rational position sizing framework.

[00:21:59]1 to 3% of your total investable portfolio spread across the category, not concentrated in a single name.

[00:22:07]If you are right and any one of these stocks delivers a 10x return, that 1 to 3% becomes 10 to 30% of your portfolio and you take profits.

[00:22:18]If you are wrong and the position goes to zero, you lose 1 to 3% of your portfolio. You retire roughly on schedule and you move on.

[00:22:28]That is the asymmetric risk management structure that separates intelligent speculation from gambling.

[00:22:34]People who go all in on stories like this are not investors. They are lottery ticket buyers who happen to be given specific ticker symbols. Here is your binary choice. And I am going to make it as clear as I possibly can because clarity is the only thing that produces action and action is the only thing that produces results.

[00:22:55]On one side of this choice, you do nothing. You wait for CNBC to cover this story. You wait until your colleague at work mentions one of these tickers, you wait until the stocks have already moved 60, 70, 80% from where they sit today, and then you call it a confirmed trend, and you buy at the top like every other retail investor who has ever lost money following the crowd.

[00:23:18]That path is comfortable right now, and it is financially devastating over time.

[00:23:23]On the other side of this choice, you do the work.

[00:23:27]You take the framework I gave you today.

[00:23:29]Gross margin.

[00:23:31]Patent durability.

[00:23:32]Revenue status.

[00:23:34]And you apply it. You size the position intelligently at 1 to 3%. You understand the catalyst calendar for Compass.

[00:23:42]You understand that Atai gives you diversified exposure, and that GH Research is the highest risk, highest potential reward name in the group.

[00:23:52]You monitor the FDA timeline. You know in advance what you will do if the approval comes through, and what you will do if it does not. That path requires discipline, and it requires you to act before the consensus tells you it is safe to act.

[00:24:05]The entire history of wealth creation in financial markets is a history of people who move before the crowd and size their positions with intelligence rather than emotion.

[00:24:15]The $400 billion market Trump unlocked is real. The patient demand is real.

[00:24:21]The Johnson & Johnson precedent is real.

[00:24:25]What is not yet real is whether you are the kind of investor who acts on intelligence, or the kind who watches other people act on it and wonders how they always seem to know first.